The Journal of antimicrobial chemotherapy · 2004
Susceptibility of porcine cytomegalovirus to antiviral drugs.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fryer Jacqueline F L, Griffiths Paul D, Emery Vincent C, Clark Duncan A
Аннотация
OBJECTIVES: Re-activation of porcine cytomegalovirus (PCMV) in the xenograft has been reported in pig-to-baboon models of xenotransplantation and is associated with invasive disease and consumptive coagulopathy. If xenotransplantation of porcine organs into human recipients is to proceed, donor organs will have to be free from a wide range of infectious agents including PCMV. However, it is prudent to characterize the antiviral susceptibility of this virus. We therefore investigated the effect of selected antiviral agents, currently licensed for the treatment of human herpesvirus infections, on PCMV replication.
METHODS: Antiviral susceptibility was determined using real-time PCR and indirect immunofluorescence measurements in a porcine fallopian tube cell line infected with PCMV.
RESULTS: PCMV replication was significantly inhibited by ganciclovir and cidofovir (both EC(50) < 1 mg/L) and to a lesser extent by foscarnet (EC(50) within range 25-50 mg/L) and aciclovir (EC(50) > 25 mg/L).
CONCLUSIONS: These results show that, if it proves necessary, ganciclovir and cidofovir should be considered as first-line drugs to treat PCMV infections in xenograft recipients.
METHODS: Antiviral susceptibility was determined using real-time PCR and indirect immunofluorescence measurements in a porcine fallopian tube cell line infected with PCMV.
RESULTS: PCMV replication was significantly inhibited by ganciclovir and cidofovir (both EC(50) < 1 mg/L) and to a lesser extent by foscarnet (EC(50) within range 25-50 mg/L) and aciclovir (EC(50) > 25 mg/L).
CONCLUSIONS: These results show that, if it proves necessary, ganciclovir and cidofovir should be considered as first-line drugs to treat PCMV infections in xenograft recipients.